1. http://pistoiaalliance.org @PistoiaAlliance The Analysome a new way to find quality assays for biomarkers Pistoia Alliance Webinar, 24 th July 2014 Richard Holland, Executive Director Operations Anthony Rowe and Richard Knowles, Project Leaders

2. 2 This webinar is being recorded The recording will be made available on the Pistoia Alliance website.

3. 3 Vision of the Analysome Service Online service providing access to curated information about the availability of assays for human analytes, free to end-users Commercial and academic assays and methods Search by analyte or list of analytes (gene, protein, metabolite) Expanded search by biological pathway/network Results delivered as list of available assays –Key parameters (sensitivity, multiplexing, cost, validation status, provider…) Click to order analytes from vendors 3

4. 4 We are looking for… ~$170-$225k funding to enable commercial provision of Analysome platforms: Fully functional prototype already exists First commercial version to be made available within six months from close of fundraising 2-3 risk-shared competing market-ready solutions Open RFP invitation $60k core costs (project management, marketing and comms) Plus $55k for shared-risk funding per successful RFP respondent Minimum required is $170k to cover core costs plus funding of two respondents

5. 5 The Analysome So Far Functional prototype built for the IMI U-BIOPRED Project Thomson Reuters provided access to Cortellis Data Fusion for development of the prototype Pistoia Alliance approached by the IMI U-BIOPRED project (Unbiased biomarkers for the prediction of respiratory disease outcomes) Joint initiative with U-BIOPRED to develop the “Analysome Service” 5

6. 6 The Analysome Project Status A Pistoia Alliance – U-BIOPRED Collaborative project Scope, partner discussions Prototype, more partner discussions Webinar RFP Shared-risk project 2014Q32013Q42013Q22014Q4

7. http://pistoiaalliance.org @PistoiaAlliance Live Demonstration

8. http://pistoiaalliance.org @PistoiaAlliance Background

9. 9 Pistoia Alliance: Lowering barriers to R&D Innovation “Pistoia Alliance members aim to lower barriers to innovation by improving the interoperability of R&D business processes through precompetitive collaboration. The organization focuses on bringing stakeholders to the table to define common, conceptual steps of the life science R&D workflow.”

10. 10 Interactive Project Portfolio Platform

11. 11 Feedback interviews Better than Googling Public comments on assays more valuable than providing links to literature –Good quality control required –Manual curation a core component Useful to include full service CROs as well as vendors and academia Convenient click through to order

12. 12 Value Proposition and Stakeholders Value for Consumers: One stop shopping: Rapidly find available assays for analytes of interest (including analytes in related biological networks) Clear validity level Information exchange between users Consumer stakeholders: Translational Research, Biomarker Discovery –pharma, biotech, academia, non-profit research organisations CROs 12

13. 13 Value Proposition and Stakeholders Value for Providers: Highly effective marketing channel Opportunity to increase sales of products More participation, more coverage, more success Provider stakeholders: Assay providers –e.g. companies who sell kits / who offer assay services CROs 13

14. http://pistoiaalliance.org @PistoiaAlliance Next Steps

15. 15 Proposed project deliverables Development of Analysome platform(s): First version to be made available after six months Nine month project from completion of fund-raising to final milestone 2-3 risk-shared competing market-ready solutions Open RFP invitation Existing prototype provided for reuse –Subject to Thomson Reuters licence for Cortellis Data Fusion Approximately six months development window with milestones –Key features to be delivered earlier –Faster development an advantage A communications programme to include: Press releases at key milestones Development of promotional materials Presentation at conferences Regular user community meetings, working with U-BIOPRED

16. 16 Call to action Providers –Investing in development of the Analysome will open up a major new sales channel and associated revenue stream Consumers, e.g. pharma –Investment in this platform will pay off in terms of reduced time to find the correct analyte for future R&D projects, and in reduced wastage through a reduction in incorrect orders or failed experiments Early investors will get to shape the RFP as it is developed ~$170-$225k total funding sought Contact John Wise: execdirector@pistoiaalliance.orgexecdirector@pistoiaalliance.org Peter Boogaard will be in touch from 2 nd week of August

17. http://pistoiaalliance.org @PistoiaAlliance Q&A

18. 18 The Analysome Unmet Need  Drug R&D requires validated biomarker assays  Information on such assays is available but is neither well coordinated nor vetted  Significant time/money is spent researching the availability & quality of biomarkers  Drug companies need to reduced the costs of searching for biomarker assays (e.g. $30K to $40K)  CROs need a showcase to display their biomarker capabilities for maximum impact to multiple potential users  Academics need a simple way to find opportunities to seek new, useful biomarkers Value Proposition The Analysome will accelerate life-science R&D including translational research by:  Building an evidence-based database of assays for analytes  Standardizing knowledge & vocabulary for analyte use & assay validation  Allowing life scientists to find & utilize the best biomarkers for their research.  Allowing biomarker & diagnostic developers to understand assay availability, use & cost in the market  Fostering a community of scientific users, biomarker developers & assay service organizations  Shared project requirements: project analyst, platform pilot, socialization, service implementation & Curation  Project value for stakeholders:  FTE saving on finding the right biomarker at the right time with the right quality and the right availability  FTE saving on in-house curation of biomarker resources providing vendors a marketplace for their assays  Risk mitigation – using appropriately validated & qualified biomarkers minimizes experimental and regulatory risks High Level Implementation Timeline Q2 - 13Q4 - 13Q3 - 15Q4 - 14 Workstream Start Business Case Business Case Funding Agreed Business Case Funding Available Analysome Biomarker Service Available 18 Phase II Kickoff for Analysome 1.01.0 Q2 - 15 v2.0 v3.0 1.01.0 v1.0